Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900051 | 0.89 | SCN9A (0.38) | NPC1RAB9ASMN1; SMN2SCN9A | |
| SCHEMBL9900188 | 0.79 | MAPT (0.31) | RAB9ASCN9AALDH1A1 | |
| SCHEMBL9900224 | 0.76 | FPR2 (0.45) | — | |
| SCHEMBL9900219 | 0.74 | POLB (0.32) | — | |
| SCHEMBL9900244 | 0.71 | POLB (0.35) | SMN1; SMN2 | |
| SCHEMBL27870393 | 0.71 | PTGER1 (0.33) | NPC1RAB9AALDH1A1 | |
| SCHEMBL9900550 | 0.70 | DPP4 (0.37) | NPC1RAB9AALDH1A1PIK3CDPIK3CA | |
| SCHEMBL9900724 | 0.70 | FPR2 (0.37) | — | |
| SCHEMBL2327224 | 0.69 | — | — | |
| SCHEMBL10744688 | 0.69 | SLC6A3 (0.42) | NPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103261194-B | Oxazolyl-methyl ether derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-24 | — | — | CN | disclosed |
| EP-2649068-B1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8846733-B2 | Oxazolyl-methylether derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-09-30 | — | — | US | disclosed |
| EP-2649068-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-20130261159-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-03 | — | — | US | disclosed |
| CN-103261194-A | Oxazolyl-methyl ether derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD | 2013-08-21 | — | — | CN | disclosed |
| WO-2012077049-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261159-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | P2RX7, ADORA3, P2RX1 | NPC1 3813/4885RAB9A 4102/4885SMN1; SMN2 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.